916078-41-6

Usage

Properties

It is a chemical compound commonly used in the pharmaceutical industry as a building block for the synthesis of various pharmaceutical drugs.
It is a methyl ester derivative of 1-piperidinecarboxylic acid, 4-formyl-, which is a key intermediate in the synthesis of various drugs.
It is a white to off-white crystalline powder.
It has a molecular formula of C8H13NO2.
It has a molecular weight of 155.19 g/mol.
It is often used as a reagent in organic synthesis.
It is known for its role in the preparation of various bioactive compounds.

Specific content

1-Piperidinecarboxylic acid, 4-formyl-, methyl ester is a versatile and important chemical in the pharmaceutical industry.

Upstream product

• 916078-39-2 methyl 4-(hydroxymethyl)piperidine-1-carboxylate 
• 439944-43-1 ethyl 1-methoxycarbonyl-4-piperidinecarboxylate 
• 6457-49-4 4-piperidinemethanol 

Downstream Products

• 1104604-93-4 C₂₇H₂₉N₅O₂ 

Relevant academic research and scientific papers

Beyond organic solvents: synthesis of a 5-HT4receptor agonist in water

Reducing or eliminating organic solvent use in pharmaceutical manufacturing is perhaps the most effective way to reduce the environmental, health, and safety impacts of drug substance manufacturing. With this in mind, we have developed a process to manufacture an investigational 5-HT4receptor agonist that is conducted almost entirely in water, including multiple controlled isolations. Key transformations carried out in aqueous media include a benzimidazole cyclization, amide bond formation, reductive amination, and a selective oxidation of an aliphatic alcohol. Compared to the first-generation manufacturing process using organic solvents, the aqueous process described here uses 77% less material inputs, 94% less organic solvent, and, surprisingly, 48% less water, while improving overall yield from 35% to 56%.

Novel spiroketal pyrrolidine GSK2336805 potently inhibits key hepatitis C virus genotype 1b mutants: From lead to clinical compound

Rapid clinical progress of hepatitis C virus (HCV) replication inhibitors, including these selecting for resistance in the NS5A region (NS5A inhibitors), promises to revolutionize HCV treatment. Herein, we describe our explorations of diverse spiropyrrolidine motifs in novel NS5A inhibitors and a proposed interaction model. We discovered that the 1,4-dioxa-7-azaspiro[4.4]nonane motif in inhibitor 41H (GSK2236805) supported high potency against genotypes 1a and 1b as well as in genotype 1b L31V and Y93H mutants. Consistent with this, 41H potently suppressed HCV RNA in the 20-day RNA reduction assay. Pharmacokinetic and safety data supported further progression of 41H to the clinic.

BENZIMIDAZOLE-CARBOXAMIDE COMPOUNDS AS 5-HT4, RECEPTOR AGONISTS

The invention relates to benzimidazole-carboxamide 5-HT 4 receptor agonist compounds of formula (I) wherein R1 and X are as defined in the specification, or a pharmaceutically acceptable salt or solvate or stereoisomer thereof. The invention also relates